However, a secondary analysis of the CyNCh (Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease in Children) trial found that younger and lighter-weight children (≤65 kg) treated with cysteamine bitartrate were significantly more likely to experience improvements in liver histology and ALT levels compared to placebo [45]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.